ABRAMS CAPITAL MANAGEMENT, L.P.: NUVATION BIO INC (NUVB): Quarterly 13F Position History
As of Q1 2026, ABRAMS CAPITAL MANAGEMENT, L.P. reported 1,270,504 shares of NUVATION BIO INC (NUVB), worth $5.5M and representing 0.1% of its 13F equity book. Quarter-over-quarter share count change: 2,541,009 (-66.7%) . The position first appeared in Q1 2021 and has been disclosed across 21 13F-HR filings in Pactolio's tracked window.
- 1,270,504Shares Held (Latest Filing)
- $5.5MReported Market Value (Latest Filing)
- 0.1%Portfolio Weight (% of 13F Equity Book)
- 2,541,009Quarter-over-Quarter Share Change
- -$28.7MQuarter-over-Quarter Value Change
- 3,811,513Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 21 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q1 2026 | 1,270,504 | 2,541,009 | -66.7% | $5.5M | 0.1% | $4.3 |
| Q4 2025 | 3,811,513 | 0 | — | $34.2M | 0.6% | $9.0 |
| Q3 2025 | 3,811,513 | 0 | — | $14.1M | 0.2% | $3.7 |
| Q2 2025 | 3,811,513 | 0 | — | $7.4M | 0.1% | $1.9 |
| Q1 2025 | 3,811,513 | 0 | — | $6.7M | 0.1% | $1.8 |
| Q4 2024 | 3,811,513 | 0 | — | $10.1M | 0.2% | $2.7 |
| Q3 2024 | 3,811,513 | 0 | — | $8.7M | 0.1% | $2.3 |
| Q2 2024 | 3,811,513 | 0 | — | $11.1M | 0.2% | $2.9 |
| Q1 2024 | 3,811,513 | 0 | — | $13.9M | 0.4% | $3.6 |
| Q4 2023 | 3,811,513 | 0 | — | $5.8M | 0.2% | $1.5 |
| Q3 2023 | 3,811,513 | 0 | — | $5.1M | 0.2% | $1.3 |
| Q2 2023 | 3,811,513 | 0 | — | $6.9M | 0.2% | $1.8 |
| Q1 2023 | 3,811,513 | 0 | — | $6.3M | 0.2% | $1.7 |
| Q4 2022 | 3,811,513 | 0 | — | $7.3M | 0.3% | $1.9 |
| Q3 2022 | 3,811,513 | 0 | — | $8.5M | 0.2% | $2.2 |
| Q2 2022 | 3,811,513 | 0 | — | $12.3M | 0.3% | $3.2 |
| Q1 2022 | 3,811,513 | 0 | — | $20.0M | 0.5% | $5.3 |
| Q4 2021 | 3,811,513 | 0 | — | $32.4M | 0.7% | $8.5 |
| Q3 2021 | 3,811,513 | 0 | — | $37.9M | 0.8% | $9.9 |
| Q2 2021 | 3,811,513 | 0 | — | $35.5M | 0.8% | $9.3 |
| Q1 2021 | 3,811,513 | — | — | $34.0M | 0.8% | $8.9 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.
When did ABRAMS CAPITAL MANAGEMENT, L.P. first disclose a NUVB position in 13F-HR filings?
ABRAMS CAPITAL MANAGEMENT, L.P. first reported NUVATION BIO INC (NUVB) on its 13F-HR filing for the period ending 2021-03-31 (Q1 2021). The position has appeared on 21 reported quarters within Pactolio's tracked window.
What was ABRAMS CAPITAL MANAGEMENT, L.P.'s most recent quarter-over-quarter share-count change in NUVB?
Between Q4 2025 and Q1 2026, ABRAMS CAPITAL MANAGEMENT, L.P. reduced its NUVB position by 2,541,009 shares (-66.7%), leaving 1,270,504 shares at a market value of $5.5M.
Does the implied price-per-share represent ABRAMS CAPITAL MANAGEMENT, L.P.'s cost basis in NUVB?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.